Practical experience of secukinumab in the treatment of psoriasis: experience from a single centre.
Laoise R GriffinJennifer BoggsBart RamsayCaitriona HackettKashif AhmadMaeve LynchPublished in: Irish journal of medical science (2020)
Secukinumab is a novel anti-interleukin-17A agent that has achieved a 75% decrease from baseline in Psoriasis Area and Severity Index (PASI 75) in 77-81% of patients treated in clinical trials Langley et al. (N Engl J Med 371:326-338, 2014). There is limited data on the use of secukinumab outside of clinical trials. We provide real-world data on the efficacy and safety of secukinumab in patients with severe psoriasis attending an outpatient dermatology service. In our retrospective review, we demonstrate (PASI 75) a response rate of 47% in patients previously treated with multiple systemic and biologics. Our efficacy is comparable to that seen in the Signature study who examined similar populations. Response was maintained at follow-up of almost 1 year with acceptable safety data. Patients with psoriatic arthritis were more likely to remain on secukinumab than those without at last clinic follow-up.
Keyphrases
- ankylosing spondylitis
- clinical trial
- electronic health record
- end stage renal disease
- big data
- newly diagnosed
- rheumatoid arthritis
- ejection fraction
- mental health
- chronic kidney disease
- disease activity
- primary care
- prognostic factors
- peritoneal dialysis
- early onset
- randomized controlled trial
- artificial intelligence
- phase ii
- open label
- atopic dermatitis
- data analysis
- deep learning